Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Infant Bacterial Therapeutics

Infant Bacterial Therapeutics
2013 FOUNDED
PUBLIC STATUS
1-10 EMPLOYEES
IBT B STOCK SYMBOL
$18.24 SHARE PRICE (As of Thursday Closing)
Description

Developer of necrotizing enterocolitis (NEC) prevention drugs. The company develops pharmaceutical drugs for the prevention of necrotising enterocolitis (NEC) in premature infants.

Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Stock Exchange
STO
Primary Office
  • Gamla Brogatan 11
  • 111 20 Stockholm
  • Sweden

+46 08-410 000 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Infant Bacterial Therapeutics’s full profile, request a free trial.

Infant Bacterial Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$9.28 - $22.82 $198M $18.55 -$0.68 38.7K 11.2M

Infant Bacterial Therapeutics Financials Summary

In Thousands,
USD
TTM
30-Sep-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
FY 2014
31-Dec-2014
Enterprise Value 78,082 3,624
Revenue 40 19 0 0
EBITDA (4,715) (4,445) (2,443) (961)
Net Income (4,716) (4,447) (3) (984)
Total Assets 10,224 12,090 9,812 1,872
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Infant Bacterial Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Infant Bacterial Therapeutics‘s full profile, request access.

Request full access to PitchBook

Infant Bacterial Therapeutics Executive Team (4)

Name Title Board
Seat
Contact
Info
Staffan Strömberg Ph.D Chief Executive Officer
Anders Kronström Chief Technology Officer
Sanjiv Sharma Chief Commercial Officer

1 Former Executive

You’re viewing 3 of 4 executives. Get the full list »